Mersana Therapeutics Inc (MRSN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Mersana Therapeutics Inc (MRSN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7591
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:61
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp is a clinical-stage biopharmaceutical company that offers antibody drug conjugate to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes Fleximer antibody drug conjugation (ADC) platform, Dolaflexin to design ADC’s with drug-to-antibody ratios. Mersana’s Dolaflexin platform offers custom design of an ADC with specific properties to target a particular type of cancer. The company develops immunoconjugates to deliver payloads of anti tumor agents directly to cancerous cells. Its products are developed for multiple cancer indications including gastric cancer and metastatic breast cancer. Mersana is headquartered in Cambridge, Massachusetts, the US.

Mersana Therapeutics Inc (MRSN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 12
Mersana Therapeutics Raises USD35 Million in Series B Financing 14
Mersana Therapeutics Secures USD14.51 Million in Venture Funding 15
Mersana Therapeutics Raises US$5 Million In Venture Financing 16
Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 17
Mersana Therapeutics Raises Additional US$4 Million In Venture Financing 19
Partnerships 20
Mersana Therapeutics Expands Agreement with Takeda Pharma 20
Mersana Expands Co-Development Agreement with Takeda Pharma 21
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 22
Licensing Agreements 23
Mersana Therapeutics Enters into Licensing Agreement with Recepta Biopharma 23
Mersana Exercises Option for License Agreement with Millennium 24
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 25
Mersana Therapeutics Amends its Licensing Agreement with Adimab 26
Equity Offering 27
Mersana Therapeutics Plans to Raise up to USD250 in Public Offering of Securities 27
Mersana Therapeutics Raises USD75 Million in IPO 28
Mersana Therapeutics Inc – Key Competitors 30
Mersana Therapeutics Inc – Key Employees 31
Mersana Therapeutics Inc – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Aug 14, 2018: Mersana Therapeutics reports second quarter 2018 financial results 33
May 14, 2018: Mersana Therapeutics Reports First Quarter 2018 Financial Results 35
Mar 28, 2018: Mersana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 36
Nov 09, 2017: Mersana Announces Third Quarter 2017 Financial Results and Provides Business Updates 38
Aug 11, 2017: Mersana Announces Second Quarter 2017 Financial Results and Provides Business Updates 40
Corporate Communications 42
Mar 19, 2018: Mersana Therapeutics Appoints Willard H. Dere As Board Director 42
Mar 12, 2018: Mersana Appoints David A. Spellman as Chief Financial Officer 43
Sep 05, 2017: Mersana Appoints Lawrence M. Alleva to Board of Directors 44
Jan 05, 2017: Mersana Therapeutics Appoints Andrew A. F. Hack, M.D., Ph. D. to Board of Directors 45
Product News 46
03/02/2017: Mersana Presents New Data on Investigational Cancer Antibody Drug Conjugate at American Association of Cancer Research Annual Meeting 46
Product Approvals 47
Sep 17, 2018: Mersana Therapeutics provides update on XMT-1536 47
Clinical Trials 48
Sep 25, 2018: Mersana Therapeutics presents new preclinical data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer 48
Jun 04, 2018: Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018 49
May 22, 2018: Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual Meeting 50
Apr 17, 2018: Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018 51
Apr 09, 2018: Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018 52
Dec 12, 2017: Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors 53
Oct 30, 2017: Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b 54
Oct 30, 2017: Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference 55
Oct 23, 2017: Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 56
Jun 05, 2017: Mersana Confirms Clinical Trial Progress on Lead Oncology Program at ASCO 2017 57
Apr 02, 2017: Mersana Therapeutics Presents Preclinical Data on XMT-1522 Supporting Efficacy and Tolerability 58
Other Significant Developments 59
Jan 08, 2018: Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals 59
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mersana Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 12
Mersana Therapeutics Raises USD35 Million in Series B Financing 14
Mersana Therapeutics Secures USD14.51 Million in Venture Funding 15
Mersana Therapeutics Raises US$5 Million In Venture Financing 16
Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 17
Mersana Therapeutics Raises Additional US$4 Million In Venture Financing 19
Mersana Therapeutics Expands Agreement with Takeda Pharma 20
Mersana Expands Co-Development Agreement with Takeda Pharma 21
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 22
Mersana Therapeutics Enters into Licensing Agreement with Recepta Biopharma 23
Mersana Exercises Option for License Agreement with Millennium 24
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 25
Mersana Therapeutics Amends its Licensing Agreement with Adimab 26
Mersana Therapeutics Plans to Raise up to USD250 in Public Offering of Securities 27
Mersana Therapeutics Raises USD75 Million in IPO 28
Mersana Therapeutics Inc, Key Competitors 30
Mersana Therapeutics Inc, Key Employees 31

List of Figures
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Mersana Therapeutics Inc (MRSN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sinopec Oilfield Service Corp (600871):企業の財務・戦略的SWOT分析
    Sinopec Oilfield Service Corp (600871) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • General Dynamics Corporation:企業の戦略・SWOT・財務情報
    General Dynamics Corporation - Strategy, SWOT and Corporate Finance Report Summary General Dynamics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Siddhartha Bank Ltd:電力:M&Aディール及び事業提携情報
    Summary Siddhartha Bank Ltd (Siddhartha Bank) is a financial service provider that offers personal and corporate banking solutions. The company offers savings accounts, deposit accounts, loans, card, nostro accounts, mutual funds and fixed deposits. It provides business loans, home loans, auto loans …
  • Qioptiq Group:企業の戦略的SWOT分析
    Qioptiq Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Qiagen NV (QIA):医療機器:M&Aディール及び事業提携情報
    Summary Qiagen NV (Qiagen) is a provider of molecular testing solutions. The company offers consumable products, instruments and automation systems. The company’s sample technologies help isolate and process DNA, RNA and proteins from samples such as blood and tissue; assay technologies to identify …
  • Unibail-Rodamco-Westfield Se
    Unibail-Rodamco-Westfield Se - Strategy, SWOT and Corporate Finance Report Summary Unibail-Rodamco-Westfield Se - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Comet Ridge Ltd (COI):石油・ガス:M&Aディール及び事業提携情報
    Summary Comet Ridge Ltd (CRL) is an oil and gas exploration and production company that acquires, explores and develops oil and gas properties. The company holds interests in Mahalo project located in the Denison trough area of Queensland's Bowen Basin near Rolleston. It also holds interest in PEL 6 …
  • Eddie Bauer LLC:企業の戦略的SWOT分析
    Eddie Bauer LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Movenpick Schweiz AG:企業の戦略・SWOT・財務情報
    Movenpick Schweiz AG - Strategy, SWOT and Corporate Finance Report Summary Movenpick Schweiz AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • University of Arizona-医療機器分野:企業M&A・提携分析
    Summary University of Arizona (UA) is a healthcare research university that offers undergraduate and graduate degrees. The university’s academic departments include cancer biology graduate interdisciplinary program, cancer biology, cellular and molecular medicine, cancer center, center for education …
  • JSC Inter RAO:企業のM&A・事業提携・投資動向
    JSC Inter RAO - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JSC Inter RAO Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Edison SpA:企業の発電所・SWOT分析2018
    Edison SpA - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • Intelligent Energy Ltd:電力:M&Aディール及び事業提携情報
    Summary Intelligent Energy Ltd (Intelligent Energy), a subsidiary of Intelligent Energy Holdings plc, is a diversified company that offers fuel cell stack technology. The company operates through its divisions such as stationary power, automotive and consumer electronics. Its consumer electronics di …
  • Tricida Inc (TCDA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company. The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases. Its lead drug candidate TRC101, is under clinical dev …
  • Exterran Corp (EXTN):企業の財務・戦略的SWOT分析
    Exterran Corp (EXTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Suedzucker Ag:企業の戦略・SWOT・財務分析
    Suedzucker Ag - Strategy, SWOT and Corporate Finance Report Summary Suedzucker Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Enerkem Inc:企業の戦略的SWOT分析
    Enerkem Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Daigas Group:企業の戦略・SWOT・財務分析
    Daigas Group - Strategy, SWOT and Corporate Finance Report Summary Daigas Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • BioMarin Pharmaceutical Inc (BMRN)-医療機器分野:企業M&A・提携分析
    Summary BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals that treat serious diseases and medical conditions. The company offers products for the treatment of various diseases such as Kyndrisa (drisapersen), Duchenne mu …
  • Sunsweet Growers Inc.:戦略・SWOT・企業財務分析
    Sunsweet Growers Inc. - Strategy, SWOT and Corporate Finance Report Summary Sunsweet Growers Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆